Eurospital S. p. A.   
C/O Ms. Catherine L. Wong   
U.S. Agent   
2832 Via Pacheco   
Palos Verdes Estates, CA 90274

Re: K160447 Trade/Device Name: Calprest®NG Regulation Number: 21 CFR 866.5180 Regulation Name: Fecal Calprotectin Immunological Test System Regulatory Class: II Product Code: NXO Dated: September 29, 2016 Received: October 3, 2016

Dear Ms. Wong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the

electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Kelly Oliner -S

FORK   
Leonthena R. Carrington, MS, MBA, MT(ASCP)   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

<table><tr><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.</td></tr><tr><td>510(k) Number (if known) K160447</td><td></td></tr><tr><td>Device Name Calprest®NG</td><td></td></tr></table>

Indications for Use (Describe)

Calprest®NG is a quantitative ELISA for detecting concentration of fecal calprotectin, which can be used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# 510(k) Summary

This summary of $5 1 0 ( \mathsf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k160447

1. Submitter’s name, address, telephone, contact person, and the date the summary was prepared:

Submitter’s Name: Eurospital S.p.A.   
Submitter’s Address: Via Flavia, 122 – I 34147 Trieste, Italy   
Submitter’s Telephone Number: Tel. $+ 3 9$ 0408997285   
Submitter’s Contact Name: Claudia Brandolin, Quality Assurance Manager

2. Name of the device, including the trade or proprietary name, the common or usual name and the classification name:

Proprietary Name: Common Name: Classification Name:

Calprest® NG   
Fecal calprotectin immunological test system   
Calprotectin, Fecal; 21 CFR 866.5180   
Class II   
Product Code: NXO

3. Identification of the legally marketed device to which the submitter claims substantial equivalence:

Predicate Device Name:

Calprest® 510(k) Number: K130945 Regulation Number: 21CFR866.5180 Regulation Class: Class II

# 4. Description of the device

Calprest® NG is an enzyme-linked immunosorbent assay (ELISA) system with colorimetric detection based on the use of antibodies against calprotectin. Calprotectin present in the diluted sample is bound by the antibody adsorbed to the surface of the plastic well. The enzyme conjugated antibody binds to the captured antigen and subsequently the enzyme catalyzes the conversion of the substrate to a colored product. The intensity of the color is proportional to the amount of conjugate bound, and thus to the amount of captured calprotectin. Concentration of calprotectin in the samples is calculated using the provided standards.

# 5. Statement of the intended use of the device

Device Intended Use:

Calprest® NG is a quantitative ELISA for detecting concentration of fecal calprotectin, which can be used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.

# 6. Summary of the technological characteristics of the device

Calprest® NG and Calprest® Test are manufactured by Eurospital S.p.A. Trieste, Italy. Comparing to Calprest® , the differences of Calprest® NG include the name of the test on the labels, detection antibody, the use of a Horse-radish peroxidase / TMB conjugate/substrate system, the provided Stop solution, the concentration of calibrators and controls in the kit and the dynamic range of the assay.

# 7. Summary of performance characteristics

# 7.1. Expected Values

<table><tr><td rowspan=1 colspan=1>Calprotectin Concentration</td><td rowspan=1 colspan=1>Interpretation</td><td rowspan=1 colspan=1>Follow-Up</td></tr><tr><td rowspan=1 colspan=1>27.1 - &lt;50 mg/kg</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>None</td></tr><tr><td rowspan=1 colspan=1>50 - 120 mg/kg</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Re-evaluate at 4-6 weeks</td></tr><tr><td rowspan=1 colspan=1>&gt;120 mg/kg</td><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>Repeat as clinically indicated</td></tr></table>

# 7.2. Clinical Performance

<table><tr><td rowspan=1 colspan=1>Borderline valuesconsidered Positive</td><td rowspan=1 colspan=2>IBD$Positive    Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>PositiveCalprest®NG      NegativeTotal</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>137</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>136</td></tr><tr><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>273</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=2>95%C.1$.(89.2% - 97.8%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>90.2%</td><td rowspan=1 colspan=2>95%C.I.(84.1% - 94.5%)</td></tr><tr><td rowspan=1 colspan=1>PPV*</td><td rowspan=1 colspan=1>89.8%</td><td rowspan=1 colspan=2>95%C.I.(83.4% - 94.3%)</td></tr><tr><td rowspan=1 colspan=1>NPV**</td><td rowspan=1 colspan=1>94.9%</td><td rowspan=1 colspan=2>95%C.I.(89.7% - 97.9%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Borderline valuesconsidered Negative</td><td rowspan=1 colspan=2>IBDPositive     Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>PositiveCalprest®NG      NegativeTotal</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>162</td></tr><tr><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>273</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>83.1%</td><td rowspan=1 colspan=2>(95%C.I. 75.5% - 89.1%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=2>(95%C.I.94.0% - 99.6%)</td></tr><tr><td rowspan=1 colspan=1>PPV*</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=2>(95%C.I.92.3% - 99.4%)</td></tr><tr><td rowspan=1 colspan=1>NPV**</td><td rowspan=1 colspan=1>86.4%</td><td rowspan=1 colspan=2>(95%C.I.80.2% - 91.3%)</td></tr></table>

\$ IBD: Inflammatory Bowel Disease \* PPV: Positive Predictive Value \*\* NPV: Negative Predictive Value § CI: Confidence Interval

# 7.3. Extraction Reproducibility

Values are reported in mg/kg

<table><tr><td rowspan=1 colspan=1>Extracted stool sample No.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/kg)</td><td rowspan=1 colspan=1>29.6</td><td rowspan=1 colspan=1>52.7</td><td rowspan=1 colspan=1>227.0</td><td rowspan=1 colspan=1>1973.3</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>15.5</td><td rowspan=1 colspan=1>117.3</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>5.9</td></tr></table>

# 7.4. Comparison Study

# 7.4.1. Device Comparison

Reagents: Calprest $\mathcal { \bar { \mathbf { \rho } } } _ { \mathsf { N G } }$ , code 9069, (manufactured by Eurospital S.p.A.) Predicate device: Calprest®, code 9031 (k130945, manufactured by Eurospital S.p.A.)

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New device</td><td rowspan=1 colspan=1>Predicate (K130945)</td></tr><tr><td rowspan=1 colspan=1>cYanmaGYellowb</td><td rowspan=1 colspan=1>Calprest®NG, code 9069</td><td rowspan=1 colspan=1>Calprest®, code 9031</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Calprest®NG is a quantitative ELISAfor detecting concentration of fecalcalprotectin, which can be used as anin vitro diagnostic to aid in thediagnosis of Inflammatory BowelDiseases (IBD), specifically Crohn&#x27;sdisease and ulcerative colitis, and todifferentiate IBD from Irritable BowelSyndrome (IBS) in conjunction withother clinical and laboratory findings.</td><td rowspan=1 colspan=1>Calprest® is a quantitative ELISA kit fordetecting concentration of fecalcalprotectin which can be used as invitro diagnostic to aid in the diagnosisof Inflammatory Bowel Diseases (IBD,Crohn&#x27;s disease and ulcerative colitis)and to differentiate IBD from IrritableBowel Syndrome (IBS) in conjunctionwith other clinical and laboratoryfindings.</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>ELISA</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Calprotectin</td><td rowspan=1 colspan=1>Calprotectin</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Quantitative</td></tr><tr><td rowspan=1 colspan=1>Positive and Negativecontrols</td><td rowspan=1 colspan=1>Ready to use</td><td rowspan=1 colspan=1>Ready to use</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Stool</td><td rowspan=1 colspan=1>Stool</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>1-5 g stool</td><td rowspan=1 colspan=1>1-5 g stool</td></tr><tr><td rowspan=1 colspan=1>Extraction solution</td><td rowspan=1 colspan=1>2.5x concentrate</td><td rowspan=1 colspan=1>2.5x concentrate</td></tr><tr><td rowspan=1 colspan=1>Sample buffer diluent</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>10x concentrate</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>20x concentrate</td><td rowspan=1 colspan=1>20x concentrate</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>96 well microtiter plate</td><td rowspan=1 colspan=1>96 well microtiter plate</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>50 mg/kg (μg/g)</td><td rowspan=1 colspan=1>50 mg/kg (μg/g)</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New device</td><td colspan="1" rowspan="1">Predicate (K130945)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Calprest®NG, code 9069</td><td colspan="1" rowspan="1">Calprest®, code 9031</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">6 levels:0, 2.5, 12.5, 25, 50, 150 ng/ml</td><td colspan="1" rowspan="1">6 levels:6.25, 12.5, 25, 50, 100, 200 ng/ml</td></tr><tr><td colspan="1" rowspan="1">Sample dilution</td><td colspan="1" rowspan="1">1:20000</td><td colspan="1" rowspan="1">1: 2500</td></tr><tr><td colspan="1" rowspan="1">Incubation time</td><td colspan="1" rowspan="1">60-30-15 minutes at RoomTemperature (RT)</td><td colspan="1" rowspan="1">45-45-30 minutes at RT</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">HRP Horse Radish Peroxidase (IgGmouse)</td><td colspan="1" rowspan="1">Alkaline phosphatase (IgG, rabbit)</td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="1" rowspan="1">TMB</td><td colspan="1" rowspan="1">pNPP</td></tr><tr><td colspan="1" rowspan="1">OD Reading</td><td colspan="1" rowspan="1">450 nm</td><td colspan="1" rowspan="1">405 nm</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">H2SO4 (0.5M)</td><td colspan="1" rowspan="1">None</td></tr></table>

# 7.4.2. Method Comparison

<table><tr><td>Borderline Value considered I as Positive</td><td colspan="4">Calprest®</td></tr><tr><td rowspan="3">Calprest®NG</td><td rowspan="3">Pos Neg</td><td>Pos</td><td>Neg</td><td rowspan="3">113 44 157</td></tr><tr><td>113</td><td>0</td></tr><tr><td>4 117</td><td>40</td></tr><tr><td>Positive Agreement</td><td>96.6%</td><td colspan="3">40 (95% C.I. 91.5% - 98.7%)</td></tr><tr><td></td><td></td><td colspan="3"></td></tr><tr><td>Negative Agreement Overall agreement</td><td>100.0% 97.5%</td><td colspan="3">(95% C.I. 91.2% - 100.0%) (95% C.I. 93.9% - 99.0%)</td></tr></table>

Deming Regression Analysis (y: Calprest® NG, x: Calprest® )   

<table><tr><td>Borderline Value considered as Negative</td><td colspan="4">Calprest®</td></tr><tr><td rowspan="4">Calprest®NG</td><td rowspan="4">Pos Neg</td><td>Pos</td><td>Neg</td><td rowspan="4">76 81</td></tr><tr><td>73</td><td>3</td></tr><tr><td>3</td><td>78</td></tr><tr><td>76</td><td>81</td></tr><tr><td>Positive Agreement</td><td>96.1%</td><td colspan="3">157 (95% C.I. .89.0% - 98.6%)</td></tr><tr><td>Negative Agreement</td><td>96.3%</td><td colspan="3">(95% C.I. 89.7% - 98.7%)</td></tr><tr><td>Overall agreement</td><td>96.2%</td><td colspan="3">(95% C.I. 91.9% - 98.2%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept (95% CI)</td></tr><tr><td rowspan=1 colspan=1>Y = 0.92x + 0.13</td><td rowspan=1 colspan=1>0.92 (0.84 to 1.01)</td><td rowspan=1 colspan=1>0.13 (-4.64 to 4.90)</td></tr></table>

# 7.5. Precision

7.5.1. Single-Site Precision Evaluation study: Results   
7.5.2. Multisite Precision Evaluation Study: Results   

<table><tr><td rowspan="2">Sample ID°#</td><td rowspan="2">N</td><td rowspan="2">mean (mg/kg)</td><td colspan="2">Within Run</td><td colspan="2">Between Run</td><td colspan="2">Between Day</td><td colspan="2">Between Operator</td><td colspan="2">Total</td></tr><tr><td colspan="2">SD %CV</td><td colspan="2">SD %CV</td><td colspan="2">SD %CV</td><td colspan="2">SD %CV</td><td colspan="2">SD %CV</td></tr><tr><td>1</td><td>120 170.88</td><td></td><td>3.40</td><td>2.0%</td><td>6.77</td><td>4.0%</td><td>5.51</td><td>3.2%</td><td>0.80</td><td>0.5%</td><td>9.40</td><td>5.5%</td></tr><tr><td>2</td><td>120</td><td>741.60</td><td>17.38</td><td>2.3%</td><td>43.12</td><td>5.8%</td><td>55.37</td><td>7.5%</td><td>0.00</td><td>0.0%</td><td>72.30</td><td>9.7%</td></tr><tr><td>3</td><td>120</td><td>248.74</td><td>6.44</td><td>2.6%</td><td>11.98</td><td>4.8%</td><td>12.21</td><td>4.9%</td><td>0.00</td><td>0.0%</td><td>18.28</td><td>7.3%</td></tr><tr><td>4</td><td>120</td><td>42.60</td><td>1.28</td><td>3.0%</td><td>4.30</td><td>10.1%</td><td>0.00</td><td>0.0%</td><td>0.55</td><td>1.3%</td><td>4.52</td><td>10.6%</td></tr><tr><td>5</td><td>120</td><td>1193.10</td><td>52.91</td><td>4.4%</td><td>73.33</td><td>6.1%</td><td>118.78</td><td>10.0%</td><td>60.32</td><td>5.1%</td><td>161.01</td><td>13.5%</td></tr><tr><td>6</td><td>120</td><td>1006.17</td><td>41.69</td><td>4.1%</td><td>39.67</td><td>3.9%</td><td>55.80</td><td>5.5%</td><td>28.24</td><td>2.8%</td><td>84.98</td><td>8.4%</td></tr><tr><td>7</td><td>120</td><td>2267.29</td><td>223.08</td><td>9.8%</td><td>83.22</td><td>3.7%</td><td>155.52</td><td>6.9%</td><td>58.33</td><td>2.6%</td><td>290.31</td><td>12.8%</td></tr></table>

<table><tr><td rowspan="2">Sample ID#</td><td rowspan="2">N</td><td rowspan="2">mean (mg/kg)</td><td>Repeatability</td><td></td><td>Within-Site Precision</td><td>Reproducibility</td><td></td></tr><tr><td>SD</td><td>%CV</td><td>SD %CV</td><td>SD</td><td>%CV</td></tr><tr><td>A</td><td>75</td><td>433.80</td><td>13.43</td><td>3.1%</td><td>63.99</td><td>14.8%</td><td>64.55</td><td>14.9%</td></tr><tr><td>B</td><td>75</td><td>36.54</td><td>3.69</td><td>10.1%</td><td>5.11</td><td>14.0%</td><td>5.11</td><td>14.0%</td></tr><tr><td>C</td><td>75</td><td>1180.64</td><td>71.08</td><td>6.0%</td><td>156.16</td><td>13.2%</td><td>156.16</td><td>13.2%</td></tr><tr><td>D</td><td>75</td><td>682.76</td><td>35.88</td><td>5.3%</td><td>49.57</td><td>7.3%</td><td>78.95</td><td>11.6%</td></tr><tr><td>E</td><td>75</td><td>1629.44</td><td>96.29</td><td>5.9%</td><td>214.76</td><td>13.2%</td><td>226.84</td><td>13.9%</td></tr><tr><td>F</td><td>75</td><td>62.08</td><td>4.19</td><td>6.8%</td><td>5.64</td><td>9.1%</td><td>8.68</td><td>14.0%</td></tr><tr><td>G</td><td>75</td><td>356.84</td><td>12.00</td><td>3.4%</td><td>30.07</td><td>8.4%</td><td>51.93</td><td>14.6%</td></tr><tr><td>H</td><td>75</td><td>2152.20</td><td>173.58</td><td>8.1%</td><td>308.13</td><td>14.3%</td><td>312.19</td><td>14.5%</td></tr></table>

<table><tr><td rowspan="2">Sample ID#</td><td colspan="2">Repeatability 95% Cls</td><td colspan="2">Within-Site Precision 95% Cls</td><td colspan="2">Reproducibility 95% Cls</td></tr><tr><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>A</td><td>11.395 to 16.346</td><td>2.6% to 3.8%</td><td>46.388 to 103.087</td><td>10.7% to 23.8%</td><td>47.256 to 101.796</td><td>10.9% to 23.5%</td></tr><tr><td>B</td><td>3.132 to 4.493</td><td>8.6% to 12.3%</td><td>4.166 to 6.611</td><td>11.4% to 18.1%</td><td>4.166 to 6.611</td><td>11.4% to 18.1%</td></tr><tr><td>C</td><td>60.329 to 86.539</td><td>5.1% to 7.3%</td><td>117.995 to 230.930</td><td>10.0% to 19.6%</td><td>119.470 to 225.503</td><td>10.1% to 19.1%</td></tr><tr><td>D</td><td>30.452 to 43.682</td><td>4.5% to 6.4%</td><td>40.416 to 64.137</td><td>5.9% to 9.4%</td><td>49.284 to 193.644</td><td>7.2% to 28.4%</td></tr><tr><td>E</td><td>81.724 to 117.230</td><td>5.0% to 7.2%</td><td>162.277 to 317.595</td><td>10.0% to 19.5%</td><td>168.946 to 345.240</td><td>10.4% to 21.2%</td></tr><tr><td>F</td><td>3.559 to 5.105</td><td>5.7% to 8.2%</td><td>4.634 to 7.222</td><td>7.5% to 11.6%</td><td>5.419 to 21.291</td><td>8.7% to 34.3%</td></tr><tr><td>G</td><td>10.186 to 14.611</td><td>2.9% to 4.1%</td><td>22.561 to 45.073</td><td>6.3% to 12.6%</td><td>31.114 to 149.229</td><td>8.7% to 41.8%</td></tr><tr><td>H</td><td>147.319 to 211.322</td><td>6.8% to 9.8%</td><td>240.599 to 428.660</td><td>11.2% to 19.9%</td><td>242.642 to 437.935</td><td>11.3% to 20.3%</td></tr></table>

# 7.6. Linearity

# 7.6.1. Matrix Linearity

<table><tr><td rowspan=1 colspan=1>Test Rangeμg/g (mg/kg)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept (95% CI)</td><td rowspan=1 colspan=1>R{2}$</td><td rowspan=1 colspan=1>% Recovery Rate(Obtained/Theoretical)</td></tr><tr><td rowspan=1 colspan=1>25.21 - 3066.02</td><td rowspan=1 colspan=1>1.01 (0.99 - 1.04)</td><td rowspan=1 colspan=1>9.28 (-26.54 - 45.10)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>86.91% - 112.84%</td></tr></table>

# 7.6.2. Aqueous Linearity

<table><tr><td rowspan=1 colspan=1>Test Range µg/g(mg/kg)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept (95% CI)</td><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>% Recovery Rate(Obtained/Theoretical)</td></tr><tr><td rowspan=1 colspan=1>27.81 - 2889.04</td><td rowspan=1 colspan=1>1.03 (1.01 - 1.06)</td><td rowspan=1 colspan=1>-5.75 (-36.40 - 24.91)</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>93.00 - 118.68</td></tr></table>

![](images/3797ce1b7a20b6b2faf5ef386b3c7f392568b776e12920ba9ca10e78e34af671.jpg)

![](images/af2c43830eb21e56fb8be685444d57e189b8aa1a0d8c7ef33e737ea9466752d5.jpg)  
Aqueous linearity graph

Matrix linearity graph

# 7.7. Calprotectin Recovery

<table><tr><td rowspan=1 colspan=8>Calprotectin Recovery Data</td></tr><tr><td rowspan=1 colspan=1>Sample Description</td><td rowspan=1 colspan=1>#1</td><td rowspan=1 colspan=1>#2</td><td rowspan=1 colspan=1>#3</td><td rowspan=1 colspan=1>#4</td><td rowspan=1 colspan=1>#5</td><td rowspan=1 colspan=1>#6</td><td rowspan=1 colspan=1>#7</td></tr><tr><td rowspan=1 colspan=1>Baseline (mg/kg)</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>51.7</td><td rowspan=1 colspan=1>162.7</td><td rowspan=1 colspan=1>307.7</td><td rowspan=1 colspan=1>458.3</td><td rowspan=1 colspan=1>1204.0</td><td rowspan=1 colspan=1>1975.2</td></tr><tr><td rowspan=1 colspan=1>Spike Value (mg/kg)</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>115.0</td><td rowspan=1 colspan=1>115.0</td><td rowspan=1 colspan=1>115.0</td><td rowspan=1 colspan=1>115.0</td></tr><tr><td rowspan=1 colspan=1>Theoretical (Baseline+Spike) (mg/kg)</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>84.0</td><td rowspan=1 colspan=1>195.0</td><td rowspan=1 colspan=1>422.7</td><td rowspan=1 colspan=1>573.3</td><td rowspan=1 colspan=1>1319.0</td><td rowspan=1 colspan=1>2090.2</td></tr><tr><td rowspan=1 colspan=1>Observed (Baseline+Spike) (mg/kg)</td><td rowspan=1 colspan=1>42.3</td><td rowspan=1 colspan=1>79.7</td><td rowspan=1 colspan=1>200.7</td><td rowspan=1 colspan=1>425.3</td><td rowspan=1 colspan=1>592.3</td><td rowspan=1 colspan=1>1397.7</td><td rowspan=1 colspan=1>2343.8</td></tr><tr><td rowspan=1 colspan=1>Recovery (%)</td><td rowspan=1 colspan=1>101.6</td><td rowspan=1 colspan=1>94.8</td><td rowspan=1 colspan=1>102.9</td><td rowspan=1 colspan=1>100.6</td><td rowspan=1 colspan=1>103.3</td><td rowspan=1 colspan=1>106.0</td><td rowspan=1 colspan=1>112.1</td></tr></table>

# 7.8. LoB, LoD, LoQ

$$
\begin{array} { c } { { \mathsf { L o B } = 1 7 . 5 \mu \mathrm { g / g } \left( \mathsf { m g / k g } \right) } } \\ { { \mathsf { L o D } = 2 3 . 4 \mu \mathrm { g / g } \left( \mathsf { m g / k g } \right) } } \\ { { \mathsf { L o Q } = 2 7 . 1 \mu \mathrm { g / g } \left( \mathsf { m g / k g } \right) } } \end{array}
$$

# 7.9. Interfering Substance

A number of potential interfering foods, pharmaceutical and nutraceutical substances were tested.   
No interferences were observed.

<table><tr><td rowspan=3 colspan=1>Pool</td><td rowspan=1 colspan=1>No</td><td rowspan=2 colspan=10>Addition of bacterial suspensions  Table 1E coli        Salmonella spp     Shigella spp       Yesinia spp      Klebsiella spp</td></tr><tr><td rowspan=1 colspan=1>addition</td><td rowspan=1 colspan=2>E coli</td><td rowspan=1 colspan=2>Salmonella spp</td><td rowspan=1 colspan=2>Shigella spp</td><td rowspan=1 colspan=2>Yesinia spp</td></tr><tr><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>2068.6</td><td rowspan=1 colspan=1>2009.7</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>2100.1</td><td rowspan=1 colspan=1>101.5</td><td rowspan=1 colspan=1>2026.6</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>2021.1</td><td rowspan=1 colspan=1>97.7</td><td rowspan=1 colspan=1>2062.5</td><td rowspan=1 colspan=1>99.7</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>674.7</td><td rowspan=1 colspan=1>665.4</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>687.9</td><td rowspan=1 colspan=1>102.0</td><td rowspan=1 colspan=1>642.9</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>649.7</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>699.0</td><td rowspan=1 colspan=1>103.6</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>256.0</td><td rowspan=1 colspan=1>268.5</td><td rowspan=1 colspan=1>104.9</td><td rowspan=1 colspan=1>269.9</td><td rowspan=1 colspan=1>105.4</td><td rowspan=1 colspan=1>255.0</td><td rowspan=1 colspan=1>99.6</td><td rowspan=1 colspan=1>265.8</td><td rowspan=1 colspan=1>103.8</td><td rowspan=1 colspan=1>265.6</td><td rowspan=1 colspan=1>103.8</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>79.3</td><td rowspan=1 colspan=1>82.1</td><td rowspan=1 colspan=1>103.6</td><td rowspan=1 colspan=1>87.5</td><td rowspan=1 colspan=1>110.4</td><td rowspan=1 colspan=1>72.0</td><td rowspan=1 colspan=1>90.8</td><td rowspan=1 colspan=1>78.4</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>73.2</td><td rowspan=1 colspan=1>92.4</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>37.2</td><td rowspan=1 colspan=1>37.3</td><td rowspan=1 colspan=1>100.1</td><td rowspan=1 colspan=1>35.2</td><td rowspan=1 colspan=1>94.5</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>100.8</td><td rowspan=1 colspan=1>40.6</td><td rowspan=1 colspan=1>109.2</td><td rowspan=1 colspan=1>38.8</td><td rowspan=1 colspan=1>104.3</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Pool</td><td rowspan=3 colspan=2>Noadditionμg/g(mg/kg)</td><td rowspan=2 colspan=10>Addition of Drugs, Nutrients and Hemoglobin - Table 2aVancomycin     Ciproflaxin hcl      Vitamin E          Prevacid         Azathioprine</td></tr><tr><td rowspan=1 colspan=1>addition</td><td rowspan=1 colspan=2>Vancomycin</td><td rowspan=1 colspan=2>Ciproflaxin hcl</td><td rowspan=1 colspan=2>Vitamin E</td><td rowspan=1 colspan=2>Prevacid</td></tr><tr><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g (mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g (mg/kg)</td><td rowspan=1 colspan=1>∆%</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=2>2089.5</td><td rowspan=1 colspan=1>2197.4</td><td rowspan=1 colspan=1>105%</td><td rowspan=1 colspan=1>2261.1</td><td rowspan=1 colspan=1>108%</td><td rowspan=1 colspan=1>2097.6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2085.5</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1986.0</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=2>603.8</td><td rowspan=1 colspan=1>626.5</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>623.2</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>600.3</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>589.1</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>590.5</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=1 colspan=1>c</td><td rowspan=1 colspan=2>279.2</td><td rowspan=1 colspan=1>269.6</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>290.3</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>290.4</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>265.1</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>277.3</td><td rowspan=1 colspan=1>99%</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=2>82.4</td><td rowspan=1 colspan=1>79.7</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>88.1</td><td rowspan=1 colspan=1>107%</td><td rowspan=1 colspan=1>86.0</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>83.8</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>83.9</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=2>35.9</td><td rowspan=1 colspan=1>33.3</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>34.2</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>34.7</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>37.4</td><td rowspan=1 colspan=1>104%</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Pool</td><td rowspan=3 colspan=1>Noadditionμg/g(mg/kg)</td><td rowspan=2 colspan=10>Addition of Drugs, Nutrients and Hemoglobin - Table 2bPentasa           Asacol         Prednisone       Multivitamin        Hemoglobin</td></tr><tr><td rowspan=1 colspan=2>Pentasa</td><td rowspan=1 colspan=2>Asacol</td><td rowspan=1 colspan=2>Prednisone</td><td rowspan=1 colspan=2>Multivitamin</td></tr><tr><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g(mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g (mg/kg)</td><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>μg/g (mg/kg)</td><td rowspan=1 colspan=1>∆%</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>2089.5</td><td rowspan=1 colspan=1>2260.9</td><td rowspan=1 colspan=1>108%</td><td rowspan=1 colspan=1>1937.50</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>2151.30</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>2284.80</td><td rowspan=1 colspan=1>109%</td><td rowspan=1 colspan=1>2119.30</td><td rowspan=1 colspan=1>101%</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>603.8</td><td rowspan=1 colspan=1>586.7</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>599.80</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>592.90</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>589.90</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>583.70</td><td rowspan=1 colspan=1>97%</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>279.2</td><td rowspan=1 colspan=1>279.4</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>271.70</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>280.10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>272.60</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>275.40</td><td rowspan=1 colspan=1>99%</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>82.4</td><td rowspan=1 colspan=1>80.0</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>75.90</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>84.60</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>83.90</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>80.60</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>35.9</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>33.00</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>35.70</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>33.90</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>36.80</td><td rowspan=1 colspan=1>103%</td></tr></table>